Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477143 | 1.00 | LMNA (0.39) | LMNAPOLBALDH1A1RECQLSLC18A2 | |
| SCHEMBL706577 | 0.78 | CYP1A2 (0.42) | LMNAALDH1A1 | |
| SCHEMBL705280 | 0.78 | CYP1A2 (0.42) | LMNAALDH1A1 | |
| SCHEMBL3180201 | 0.77 | TDP1 (0.43) | LMNAALDH1A1SLC6A3 | |
| SCHEMBL5023130 | 0.77 | TDP1 (0.43) | LMNAALDH1A1SLC6A3 | |
| SCHEMBL3179826 | 0.77 | TDP1 (0.43) | LMNAALDH1A1SLC6A3 | |
| SCHEMBL2503654 | 0.76 | MAPT (0.45) | LMNAPOLBALDH1A1SLC18A2HTR2A | |
| SCHEMBL707123 | 0.76 | CYP1A2 (0.43) | SLC6A3 | |
| SCHEMBL705431 | 0.76 | CYP1A2 (0.43) | SLC6A3 | |
| SCHEMBL5215996 | 0.76 | SLC6A3 (0.46) | LMNARECQLSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | LMNA 3855/4885POLB 4135/4885ALDH1A1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.